Indian stocks: Visit www.stage2stocks.com →

AN2 Therapeutics, Inc.

Stage 3 · Topping · week 2

As of Oct 22, 2026, AN2 Therapeutics is in Stage 3, the topping phase, now in week 2 (since Oct 15, 2026). It closed at $3.64, 42.0% below its 52-week high and below its 200-day average, which is rising.

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. More about the company

$3.64
+1.11% today
$137M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is ANTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 24w
S4 19w
S4 14w
S2 32w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 2w → S2 24w → S3 4w → S4 19w → S1 3w → S4 14w → S1 12w → S4 6w → S1 6w → S2 3w → S3 2w → S4 12w → S1 6w → S2 5w → S3 1w → S4 9w → S1 3w → S4 1w → S2 32w → S3 1w current
Total tracked: 166 weeks across 20 stage runs.

ANTX among Biotechnology18th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…18ANTXStage 3 · wk 298−24.6%
vs 52W High
-42.0%
$1.03 lo$6.28 hi
42.0% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 2
1w13w26w
Week 2, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-8.6%
200 DMA: $3.98 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.35x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-24.6%
3M
-26.0%
6M
-15.0%
YTD
+227.9%
1Y
+200.8%
Scan Membership
Breakout Watch
Latest: 2025-05-08
2 appearances in last 60 days. First seen: 2023-09-01.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 2 · Vol 0.35x
2026-10-21S3
Wk 1 · Vol 0.56x
2026-10-20S3
Wk 1 · Vol 0.48x
2026-10-19S3
Wk 1 · Vol 1.25x
2026-10-16S3
Wk 1 · Vol 1.07x
2026-10-15S32→3
Wk 1 · Vol 1.13x
2026-10-14S2
Wk 31 · Vol 1.66x
2026-10-13S2
Wk 31 · Vol 2.02x
2026-10-12S2
Wk 31 · Vol 1.17x
2026-10-09S2
Wk 31 · Vol 1.75x
2026-10-08S2
Wk 30 · Vol 1.73x
2026-10-07S2
Wk 30 · Vol 1.51x
Moving averages & range
50 DMA
$5.11
200 DMA
$3.98
52W High
$6.28
52W Low
$1.03
5D Low
$3.37
Resistance levels (recent highs)
20d High
$5.71
60d High
$6.28
120d High
$6.28
250d High
$6.28
Next resistance
+56.9%
to 20d High
ROE
-50.1%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 1.7

AN2 Therapeutics: quick answers

What stage is AN2 Therapeutics in?

As of Oct 22, 2026, AN2 Therapeutics (ANTX) is in Stage 3, the topping phase. It entered Stage 3 on Oct 15, 2026 and is in week 2. What the four stages mean

Is AN2 Therapeutics in an uptrend?

Its uptrend has stalled. AN2 Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 8.6% below its 200-day average, which is rising.

How far is AN2 Therapeutics from its 52-week high?

AN2 Therapeutics closed at $3.64 on Oct 22, 2026, 42.0% below its 52-week high of $6.28. Its 52-week low is $1.03.

How has AN2 Therapeutics performed over the past year?

As of Oct 22, 2026, AN2 Therapeutics is up 200.8% over the past year and up 227.9% so far in 2026.

Which sector and industry is AN2 Therapeutics in?

AN2 Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.